| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| β-内酰胺类抗菌药(元) | 186,456,802.32 | 793,091,320.05 | 458,520,877.90 |
| 抗胆碱和合成解痉药(元) | 99,467,013.90 | 178,218,842.77 | 79,509,325.20 |
| 喹喏酮类原料药及中间体(元) | 53,464,469.78 | - | 59,343,198.81 |
| 皮肤用抗真菌药(元) | 36,902,115.63 | 69,555,206.42 | 36,160,798.27 |
| 喹诺酮类抗菌药(元) | - | 114,440,638.89 | - |
| 其他产品(元) | 21,015,806.55 | 33,171,213.89 | 11,576,419.59 |
| 营业成本(元) | |||
| β-内酰胺类抗菌药(元) | 153,334,999.31 | 619,507,304.85 | 363,463,390.44 |
| 抗胆碱和合成解痉药(元) | 42,427,975.25 | 79,299,218.73 | 36,052,798.31 |
| 喹喏酮类原料药及中间体(元) | 41,190,001.05 | - | 53,962,396.14 |
| 皮肤用抗真菌药(元) | 20,345,685.32 | 38,868,642.60 | 19,187,488.99 |
| 喹诺酮类抗菌药(元) | - | 106,704,546.72 | - |
| 其他产品(元) | 12,412,479.39 | 19,700,714.05 | 7,880,176.68 |
| 毛利(元) | |||
| β-内酰胺类抗菌药(元) | 33,121,803.01 | 173,584,015.20 | 95,057,487.46 |
| 抗胆碱和合成解痉药(元) | 57,039,038.65 | 98,919,624.04 | 43,456,526.89 |
| 喹喏酮类原料药及中间体(元) | 12,274,468.73 | - | 5,380,802.67 |
| 皮肤用抗真菌药(元) | 16,556,430.31 | 30,686,563.82 | 16,973,309.28 |
| 喹诺酮类抗菌药(元) | - | 7,736,092.17 | - |
| 其他产品(元) | 8,603,327.16 | 13,470,499.84 | 3,696,242.91 |
| 毛利率(%) | |||
| β-内酰胺类抗菌药(%) | 17.76 | 21.89 | 20.73 |
| 抗胆碱和合成解痉药(%) | 57.34 | 55.50 | 54.66 |
| 喹喏酮类原料药及中间体(%) | 22.96 | - | 9.07 |
| 皮肤用抗真菌药(%) | 44.87 | 44.12 | 46.94 |
| 喹诺酮类抗菌药(%) | - | 6.76 | - |
| 其他产品(%) | 40.94 | 40.61 | 31.93 |
| 收入构成(%) | |||
| β-内酰胺类抗菌药(%) | 46.93 | 66.73 | 71.08 |
| 抗胆碱和合成解痉药(%) | 25.04 | 15.00 | 12.32 |
| 喹喏酮类原料药及中间体(%) | 13.46 | - | 9.20 |
| 皮肤用抗真菌药(%) | 9.29 | 5.85 | 5.61 |
| 喹诺酮类抗菌药(%) | - | 9.63 | - |
| 其他产品(%) | 5.29 | 2.79 | 1.79 |
| 毛利构成(%) | |||
| β-内酰胺类抗菌药(%) | 25.96 | 53.51 | 57.76 |
| 抗胆碱和合成解痉药(%) | 44.70 | 30.49 | 26.41 |
| 喹喏酮类原料药及中间体(%) | 9.62 | - | 3.27 |
| 皮肤用抗真菌药(%) | 12.98 | 9.46 | 10.31 |
| 喹诺酮类抗菌药(%) | - | 2.38 | - |
| 其他产品(%) | 6.74 | 4.15 | 2.25 |